% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Schmidt:186731,
      author       = {K. Schmidt and M. Leisegang$^*$ and P.-M. Kloetzel},
      title        = {{ERAP}2 supports {TCR} recognition of three immunotherapy
                      targeted tumor epitopes},
      journal      = {Molecular immunology},
      volume       = {154},
      issn         = {0161-5890},
      address      = {Amsterdam [u.a.]},
      publisher    = {Elsevier},
      reportid     = {DKFZ-2023-00083},
      pages        = {61 - 68},
      year         = {2023},
      abstract     = {The therapy of cancer by adoptive T cell transfer (ACT)
                      requires T cell receptors (TCRs) with optimal affinity for
                      HLA class I-bound peptides (pHLA-I). But not every patient
                      responds to ACT. Therefore, it is critical to understand the
                      individual factors influencing the recognition of HLA class
                      I-bound peptides (pHLA-I) by TCRs. Focusing on three
                      immunotherapy-targeted human HLA-A* 02:01-presented T cell
                      epitopes we investigated the contribution of the ER-resident
                      aminopeptidases ERAP1 and ERAP2 to TCR recognition of cancer
                      cells. We found that ERAP2 on its own, when expressed in
                      ERAP-deficient cells, elicited a strong CTL response towards
                      the Tyrosinase368–376 epitope. In vitro generated
                      TAP-dependent N-terminally extended epitope precursor
                      peptides were differently customized by ERAP1 and ERAP2 and
                      thus may serve as potential source for the
                      Tyrosinase368–376 epitope. ERAP2 also influenced
                      recognition of the gp100209–217 tumor epitope and enhanced
                      T cell recognition of the MART-126/27–35 epitope in the
                      absence of ERAP1 expression. Our results underline the
                      relevance of ERAP2 for tumor epitope presentation and TCR
                      recognition and may need to be considered when designing ACT
                      in the future.},
      cin          = {BE01},
      ddc          = {610},
      cid          = {I:(DE-He78)BE01-20160331},
      pnm          = {899 - ohne Topic (POF4-899)},
      pid          = {G:(DE-HGF)POF4-899},
      typ          = {PUB:(DE-HGF)16},
      doi          = {10.1016/j.molimm.2022.12.010},
      url          = {https://inrepo02.dkfz.de/record/186731},
}